Literature DB >> 15256675

Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke.

Jun Hatazawa1, Eku Shimosegawa, Yasuhiro Osaki, Masanobu Ibaraki, Naohiko Oku, Shinji Hasegawa, Ken Nagata, Yutaka Hirata, Yuko Miura.   

Abstract

BACKGROUND AND
PURPOSE: Angiotensin-converting enzyme (ACE) inhibitor-based therapy reduces the recurrence of stroke. The present study assessed the effects of long-term ACE inhibitor therapy on cerebral circulation in patients with previous minor stroke.
METHODS: After a run-in period, 19 patients were randomized to ACE inhibitor therapy (n=9; 4 mg of perindopril daily; mean age, 64+/-8 years; mean systolic/diastolic blood pressure [BP]+/-SD, 133+/-12/77+/-9 mm Hg) or placebo therapy (n=10; mean age, 66+/-9 years; mean BP, 139+/-10/78+/-8 mm Hg). Cerebral blood flow (CBF) was measured during hypercapnia, normocapnia, and hypocapnia using a positron emission tomography with H2(15)O at entry into the study and after 3 to 12 months. Cerebral perfusion reserve (CPR) was defined as percent CBF response to a 1 mm Hg change in arterial partial pressure of CO2 between hypercapnia and hypocapnia.
RESULTS: Systolic/diastolic BP and CBF during normocapnia showed no significant changes between entry and completion of the trial in the perindopril and placebo groups. Mean value of CPR showed a significant increase in the perindopril group (from 3.7+/-1.7%/mm Hg to 4.8+/-1.7%/mm Hg; P<0.05) but not in the placebo group (from 4.1+/-0.8%/mm Hg to 4.2+/-0.6%/mm Hg; NS). Statistical parametric mapping analysis also showed global and significant increase (P<0.01, uncorrected) in CPR in the perindopril group alone.
CONCLUSIONS: Long-term ACE inhibitor-based therapy had a beneficial effect on the cerebral circulation by improving CPR in patients with previous minor stroke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256675     DOI: 10.1161/01.STR.0000136034.86144.e9

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

Review 1.  Bringing prevention in geriatrics: evidences from cardiovascular medicine supporting the new challenge.

Authors:  Angelo Scuteri; Edward G Lakatta
Journal:  Exp Gerontol       Date:  2012-03-03       Impact factor: 4.032

Review 2.  Antihypertensive agents for aging patients who are at risk for cognitive dysfunction.

Authors:  Ihab Hajjar; Michelle Keown; Brandy Frost
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

Review 3.  Randomized clinical trials in stroke research.

Authors:  Chul Ahn; Daniel Ahn
Journal:  J Investig Med       Date:  2010-02       Impact factor: 2.895

Review 4.  The effect of antihypertensive treatment on headache and blood pressure variability in randomized controlled trials: a systematic review.

Authors:  Alastair John Stewart Webb; Peter Malcolm Rothwell
Journal:  J Neurol       Date:  2012-02-22       Impact factor: 4.849

5.  Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.

Authors:  Yang Gao; Rónán O'Caoimh; Liam Healy; David M Kerins; Joseph Eustace; Gordon Guyatt; David Sammon; D William Molloy
Journal:  BMJ Open       Date:  2013-07-25       Impact factor: 2.692

6.  The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.

Authors:  Ihab Hajjar; Meaghan Hart; William Milberg; Vera Novak; Lewis Lipsitz
Journal:  BMC Geriatr       Date:  2009-11-18       Impact factor: 3.921

Review 7.  Clinical neuroprotective drugs for treatment and prevention of stroke.

Authors:  Kiyoshi Kikuchi; Hisaaki Uchikado; Motohiro Morioka; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2012-06-21       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.